of biological therapies in RA patients. However, being a real-life setting, unknown confounding factors might generate an apparent association or mask a true correlation between the HBcAb status and clinical outcomes.
Conclusions:
Achieving REM or LDA is not the ultimate goal of treatment for patients with functional loss and/or a grotesque appearance of their hands. Further "wellness" can be achieved by surgical intervention in the affected hand, even for patients with well-controlled RA. Such intervention can also ameliorate the disease activity.
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